# Michael A. Nauck

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-a-nauck/

## Facts

| Field | Value |
| --- | --- |
| Citations | 67,741 |
| Field | Diabetes Treatment and Management |
| h-index | 112 |
| i10-index | 315 |
| Last Known Institution | Universitätsmedizin Greifswald |
| OpenAlex ID | https://openalex.org/A5067359287 |
| ORCID iD | https://orcid.org/0000-0002-5749-6954 |
| Works | 587 |

## Researcher papers

- [Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes](https://scholariq.org/papers/liraglutide-and-cardiovascular-outcomes-in-type-2-diabetes/)
- [Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach](https://scholariq.org/papers/management-of-hyperglycemia-in-type-2-diabetes-a-patient-centered-approach/)
- [Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes](https://scholariq.org/papers/management-of-hyperglycemia-in-type-2-diabetes-2015-a-patient-centered-approach/)
- [Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/albiglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and/)
- [Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial](https://scholariq.org/papers/efficacy-and-safety-of-ly3298176-a-novel-dual-gip-and-glp-1-receptor-agonist-in/)
- [Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin](https://scholariq.org/papers/dapagliflozin-versus-glipizide-as-add-on-therapy-in-patients-with-type-2/)
- [Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study](https://scholariq.org/papers/once-weekly-albiglutide-versus-once-daily-liraglutide-in-patients-with-type-2/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Pharmacology and Obesity Treatment](https://scholariq.org/topics/pharmacology-and-obesity-treatment/)

## Researcher university

- [Universitätsmedizin Greifswald](https://scholariq.org/institutions/universitatsmedizin-greifswald/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.